Marvelle Sullivan Berchtold

Founder & CEO

2019 - Current

https://www.marvelleco.com/

Independent Trustee, Baron Funds

2020

Board Member, London School of Economics North American Advisory Board

2018

Managing Director

2017 - 2019

While at JPM, Marvelle's almost exclusive focus was on forging the healthcare initiative among Amazon, Berkshire Hathaway and JPM, which resulted in the establishment of Haven

Board Member, GSK Consumer Healthcare

2015 - 2017

Global Head of M&A

2013 - 2017

As Global Head of M&A, Marvelle was responsible for leading the M&A strategy development and implementation of the Novartis Group. Since joining Novartis, she has represented the company in over $100 billion of transactions. In March 2015, she became a member of the Board of Directors of GSK Consumer Healthcare, a joint venture between GSK and Novartis. Her recent, major transactions comprised the "Novartis Portfolio Transformation"​ series of transactions, were all announced within one year of each other and include: - Acquisition of GSK's Oncology portfolio for $16 billion - Sale of Novartis Vaccines to GSK for $5.3 billion plus milestones and royalties - Establishment of the Novartis-GSK Consumer Healthcare joint venture - Sale of Novartis Animal Health to Lilly for $5.4 billion - Sale of Novartis Diagnostics (Blood Transfusion) to Grifols for $1.7 billion - Sale of Novartis Influenza Vaccines Unit to CSL for $275 million

Head of M&A Execution

2013 - 2013

Head of Legal M&A

2009 - 2012

Associate

2005 - 2008